Creative Medical Gains FDA Fast Track Status for CELZ-201-DDT in Chronic Lower Back Pain
Creative Medical Technology Holdings, Inc. has announced that its lead candidate, CELZ-201-DDT, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of degenerative disc disease (DDD). This condition is one of the primary causes of chronic lower back pain and disability worldwide.
Fast Track designation is granted to therapies that address serious health issues with significant unmet needs. The status provides benefits such as more frequent communication with the FDA, rolling submission of the Biologics License Application (BLA), and the possibility of priority review, potentially accelerating the approval process and patient access.
CELZ-201-DDT is part of the company’s AlloStem® platform and is based on allogeneic perinatal cell therapy. It is administered through minimally invasive, ultrasound-guided intramuscular injections.
The FDA decision follows clinical findings that indicate a favourable safety profile and early evidence of effectiveness, highlighting its potential to offer a new treatment option for patients living with chronic pain caused by DDD.
Degenerative disc disease affects millions globally, and current treatment options largely focus on pain management or surgical interventions. The approach taken by Creative Medical Technology Holdings seeks to target the root causes of the condition, including cellular degeneration and inflammation, to restore function and improve quality of life.
The global market for spinal disorder treatments is projected to surpass USD 20 billion by 2030, underlining the significant commercial opportunity for innovative therapies such as CELZ-201-DDT.
